Indirect immunofluorescent assay kit to simultaneously test IgG or IgM antibodies against the main ethiological bacterial agents causing respiratory tract infections: Legionella pneumophila serogroup 1, Mycoplasma pneumoniae, Coxiella burnetii, Chlamydophila pneumoniae and Chlamydophila psittaci
Simultaneous detection of the main bacteria causing atypical pneumonia
Includes 5 microorganisms (2 wells for each) for IgG and/or IgM detection
Complete kits including all the necessary reagents to perform the technique
MIF assay for more specific results in C. pneumoniae and C. psittaci
Founded in 1991, Vircell is a biotechnology company specialized in the development and production of ready-to-use reagents for the diagnosis of infectious diseases in humans by different techniques – ranging from the traditional cell culture to the most innovating developments in the field of molecular biology. Vircell has been a successful market player worldwide, distributing its products in over 80 countries across the five continents.
The in-house production of all the antigens needed for the development of its kits enables Vircell to work with independence from external suppliers. This peculiarity makes it a flexible company able to guarantee the quality of its products. The reliability of its kits is the result of strict quality controls in accordance with international standards. All distributed tests are validated and CE-marked complying with the European directive 98/79/CE. Vircell is certified ISO 13485, ISO 14001, ISO 9001 AENOR-IQNet and ISO 9001 AENOR and is involved in the process of implementation of GMP standards.